HOME >> MEDICINE >> NEWS
Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM

West Haven, CT and Emeryville, CA January 11, 2007 -- Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer. The data, as assessed by independent radiologic review, are from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) the largest randomized controlled trial ever conducted in advanced RCC.

"Historically, patients with kidney cancer have had limited treatment options and there has been a particularly critical need for new therapies to help patients with advanced disease," said co-principal investigator Ronald Bukowski, M.D., Director of the Experimental Therapeutics Program of The Cleveland Clinic Taussig Cancer Center in Cleveland, OH. "This landmark study demonstrated the efficacy, tolerability and clinical benefit of Nexavar, which has rapidly become a valuable weapon against this devastating disease."

Based on these data, Nexavar was granted U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced RCC, or kidney cancer, on December 20, 2005. Since then, Nexavar has been approved in nearly 50 countries.

"Nexavar was the first new drug approved for patients with advanced kidney cancer in over a decade," said Bill Bro, President and Chief Executive Officer of the Kidney Cancer Association (KCA). "With the advent of targeted therapies such as Nexavar, there has been remarkable change patients are experiencing improved outcomes without the toxic effects traditionally associated with chemotherapy."

Phase III Summary
More than 900 patients with advanced RCC were randomized one-to-one to receive either 400 mg Nexavar or placebo orally twice
'"/>


10-Jan-2007


Page: 1 2

Related medicine news :

1. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
2. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
3. Program announced to improve care in developing areas for patients with blood disorders
4. AstraZeneca announces SYMBICORT is now available in the US
5. Weill Cornell Medical College announces gifts totaling $400M
6. GSK announces launch of largest ever Phase III trial in lung cancer treatment
7. World first medical treatment announced by researchers
8. Cure for hepatitis C announced by VCU researcher
9. Elsevier announces launch of Brain Stimulation
10. TWAS, illycaff announce Trieste Science Prize winners 2007
11. AIUM announced Endowment for Education and Research grant recipients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2018)... ... August 15, 2018 , ... On July 30, more than 250 people ... and Century Country Club in Westchester County. The event raised over $300,000 for Calvary ... dinner, the event included a performance by mentalist and comedian Eric Dittelman, a live ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... (DSO) with nearly 400 affiliated offices across 16 states, is pleased to announce ... Diego, California. , Smile Brands will provide full-service administrative support to the practice, ...
(Date:8/11/2018)... ... August 10, 2018 , ... ... Gout Relief. , What is gout? This painful, persistent condition originates in the ... of high levels of uric acid. Other contributing factors may be medication side ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thousands of US women ... to cross-referenced data from The American Society of Plastic Surgeons (ASPS), The American ... by the FDA. As an MRI is recommended by FDA after the first ...
(Date:8/9/2018)... ... August 09, 2018 , ... RiverGlade ... an Operating Partner and will have an exclusive relationship with the firm. ... firm’s strategic planning, human capital sourcing, and deal origination, evaluation and diligence. ...
Breaking Medicine News(10 mins):
(Date:8/11/2018)... ... , ... Last month, Dr. Tim Herman, Lead Dentist at A+ Dental ... communities surrounding its capital of Asunción. Along with a team of fellow Smile ... help deliver care to over 550 individuals in need. , Outreaches were held at ...
(Date:8/9/2018)... ... August 09, 2018 , ... National Day Calendar ... named the exclusive sponsor. , “We’re honored to have been selected as this ... for CBD on a national level,” said cbdMD’s Chief Scientific Officer, Dr. Justin ...
(Date:8/7/2018)... ... August 07, 2018 , ... Braun Ambulances is honored to announce their attendance ... Convention Center in Dallas, Texas. Braun Ambulances will have four units on display at ... , Fire Rescue International (FRI) is the International Association of Fire Chiefs’ (IAFC) annual ...
Breaking Medicine Technology:
Cached News: